DANIEL CHANG: Open Payments
NPI 1922727353 · ORANGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,290 in 33 payments from 10 companies in 2025. Trend: 2023 $1,904 · 2024 $1,757 · 2025 $1,290
Food & beverage: $1,290
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $230 |
| Janssen Pharmaceuticals, Inc | 8 | $180 |
| Teva Pharmaceuticals USA, Inc. | 3 | $148 |
| Alkermes, Inc. | 2 | $140 |
| Vanda Pharmaceuticals Inc. | 2 | $139 |
| E.R. Squibb & Sons, L.L.C. | 5 | $133 |
| Axsome Therapeutics, Inc. | 1 | $124 |
| ABBVIE INC. | 4 | $93 |
| Alpha Cognition USA, Inc. | 1 | $78 |
| Lundbeck LLC | 1 | $26 |
Products named: CAPLYTA, SPRAVATO, UZEDY, FANAPT, COBENFY, Auvelity, LYBALVI, VRAYLAR.
Industry payments across CA — which companies pay providers there.
